Payment overview · 2025
General Payments
$260.29
5 reported records · 1 companies
Healthcare provider profile · identity verified
Jagat M Rawal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELMHURST, NY · NPI 1891775680
Verified facts
What the public records show
CMS Open Payments records show Jagat M Rawal, M.D. received $260.29 in general payments during 2025 across 5 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Kerendia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $260.29 | 100.0% | 5 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $260.29 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $260.29 | 5 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 781 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 523 | 122 |
| Losartan Potassium | Losartan Potassium | 464 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 462 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 353 | 80 |
| Metformin Hcl | Metformin Hcl | 307 | 75 |
| Furosemide | Furosemide | 289 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 48 |
| Gabapentin | Gabapentin | 247 | 66 |
| Simvastatin | Simvastatin | 236 | 56 |
| Montelukast Sodium | Montelukast Sodium | 234 | 96 |
| Eliquis | Apixaban | 210 | 31 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 210 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 52 |
| Omeprazole | Omeprazole | 190 | 55 |
| Famotidine | Famotidine | 177 | 33 |
| Lisinopril | Lisinopril | 170 | 38 |
| Mirtazapine | Mirtazapine | 166 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 38 |
| Labetalol Hcl | Labetalol Hcl | 149 | 34 |
| Meloxicam | Meloxicam | 143 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 43 |
| Memantine Hcl | Memantine Hcl | 123 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 36 |
| Azithromycin | Azithromycin | 105 | 69 |
| Buspirone Hcl | Buspirone Hcl | 103 | 14 |
| Glimepiride | Glimepiride | 103 | 32 |
| Jardiance | Empagliflozin | 103 | 16 |
| Donepezil Hcl | Donepezil Hcl | 102 | 20 |
| Alendronate Sodium | Alendronate Sodium | 99 | 21 |
| Carvedilol | Carvedilol | 94 | 20 |
| Allopurinol | Allopurinol | 93 | 27 |
| Glipizide | Glipizide | 93 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 15 |
| Prednisone | Prednisone | 89 | 56 |
| Xarelto | Rivaroxaban | 85 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 71 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 12 |
| Entresto | Sacubitril/Valsartan | 67 | 11 |
| Potassium Chloride | Potassium Chloride | 67 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 15 |
| Nifedipine Er | Nifedipine | 64 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 18 |
| Metformin Hcl Er | Metformin Hcl | 60 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 28 |
| Naproxen | Naproxen | 57 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Sertraline Hcl | Sertraline Hcl | 53 | 13 |
| Promethazine Hcl | Promethazine Hcl | 52 | 39 |
| Alprazolam | Alprazolam | 51 | 17 |
| Farxiga | Dapagliflozin Propanediol | 51 | 11 |
| Folic Acid | Folic Acid | 51 | suppressed |
| Ozempic | Semaglutide | 51 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 50 | 15 |
| Tradjenta | Linagliptin | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | 19 |
| Kerendia | Finerenone | 49 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 15 |
| Atenolol | Atenolol | 47 | 16 |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 38 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Finasteride | Finasteride | 41 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 35 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 36 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 14 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 23 | 17 |
| Hydrocortisone | Hydrocortisone | 23 | 13 |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | 15 |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 23 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Misoprostol | Misoprostol | 21 | suppressed |
| Repaglinide | Repaglinide | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 13 |
| Ramipril | Ramipril | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | 14 |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | 12 |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260.29 · 5 records | Bayer Healthcare Pharmaceuticals Inc. | Kerendia | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error